Essex Bio-Technology (HK:1061) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Essex Bio-Technology Limited has announced that its subsidiary has received approval to commercialize its preservative-free unit-dose Sodium Hyaluronate Eye Drops (0.3%) in the People’s Republic of China. The product is designed to treat a variety of ocular diseases and symptoms, providing a new preservative-free treatment option for conditions like dry eye syndrome. This marks a significant step for the company in expanding its portfolio of ophthalmic products in the Chinese market.
For further insights into HK:1061 stock, check out TipRanks’ Stock Analysis page.